Centessa Pharmaceuticals PLC (CNTA) Actualités

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting

BOSTON and LONDON, March 06, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a...